New insider activity at United Therapeutics ( (UTHR) ) has taken place on March 4, 2025.
In recent transactions involving United Therapeutics stock, Director Ray Kurzweil sold 15,000 shares, amounting to a total of $4,755,081. Meanwhile, Director Tommy Thompson sold 2,500 shares, with the sale valued at $795,825.
Recent Updates on UTHR stock
United Therapeutics Corp. recently reported a record-breaking revenue for 2024, driven by strong sales across its product portfolio, including Tyvaso, Remodulin, Orenitram, and Unituxin. Despite a slight sequential decline in net revenue for Q4 due to contracting adjustments, the company remains optimistic about future growth, supported by significant progress in clinical trials and strategic capital allocation. Analysts have adjusted their price targets for United Therapeutics, citing the impact of recent contracting efforts on Tyvaso’s growth trajectory and potential competitive pressures from Liquidia’s upcoming product. The company’s focus on innovation, such as the development of Ralinepag and advancements in xenotransplantation studies, underscores its commitment to addressing unmet medical needs and maintaining a robust growth trajectory.
More about United Therapeutics
YTD Price Performance: -11.15%
Average Trading Volume: 384,574
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $14.37B